Propanc Biopharma Inc (NASDAQ:PPCB – Get Free Report) shares traded up 20.6% on Monday . The company traded as high as $2.35 and last traded at $2.05. 297,311 shares traded hands during trading, an increase of 148% from the average session volume of 119,765 shares. The stock had previously closed at $1.70.
Analyst Ratings Changes
Separately, Weiss Ratings upgraded shares of Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Propanc Biopharma has a consensus rating of “Sell”.
View Our Latest Research Report on PPCB
Propanc Biopharma Trading Down 12.4%
Propanc Biopharma (NASDAQ:PPCB – Get Free Report) last posted its quarterly earnings data on Tuesday, February 17th. The company reported ($7.50) EPS for the quarter.
Institutional Investors Weigh In On Propanc Biopharma
A hedge fund recently bought a new stake in Propanc Biopharma stock. Virtu Financial LLC acquired a new position in Propanc Biopharma Inc (NASDAQ:PPCB – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned approximately 0.33% of Propanc Biopharma at the end of the most recent reporting period.
About Propanc Biopharma
Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.
The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.
Read More
- Five stocks we like better than Propanc Biopharma
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Propanc Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Propanc Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
